RA Capital Sells $390K in Werewolf Therapeutics Amidst Strategic Review
HOWL sits 20% above its 52-week low of $0.53.
Summary
A major institutional investor, RA Capital, sold $390,688 of Werewolf Therapeutics stock, further reducing its stake as the company navigates severe financial challenges and a strategic review.
Key Events · Ownership and Investor Activity · HOWL
-
10% Owner Sells Shares
RA Capital Healthcare Fund LP, a 10% owner, disposed of 565,167 shares of Werewolf Therapeutics common stock in open market sales.
-
Significant Transaction Value
The sales totaled $390,688, representing approximately 1.27% of the company's current market capitalization.
-
Ongoing Institutional Selling
This transaction continues a pattern of institutional investors reducing their holdings amidst the company's declared going concern risk and strategic review process.
-
Sales Amidst Corporate Distress
The sales occurred between May 8 and May 12, 2026, during a period where Werewolf Therapeutics is exploring strategic alternatives and has expressed substantial doubt about its ability to continue as a going concern.
Analysis · HOWL · Life Sciences
RA Capital Healthcare Fund LP, a 10% owner, sold $390,688 worth of Werewolf Therapeutics shares. This significant sale, representing over 1.2% of the company's market capitalization, occurs as Werewolf Therapeutics faces substantial doubt about its ability to continue as a going concern and is actively exploring strategic alternatives. The continued reduction of holdings by a major institutional investor reinforces the negative sentiment surrounding the company's future.
At the time of this filing, HOWL was trading at $0.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $30.7M. The 52-week trading range was $0.53 to $2.38. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.